What Is MOTS-c? Definition and What Research Reports
MOTS-c is a 16-amino-acid peptide encoded inside the mitochondrial genome rather than the cell nucleus, which is why it is classed as a mitochondrial-derived peptide. Researchers first described it in 2015 and reported that it acted on metabolic pathways in cell and rodent models. Later laboratory work examined its movement into the nucleus during metabolic stress, its binding to the kinase CK2, and effects in muscle, islet, liver and cartilage models. Evidence remains largely preclinical and mechanistic.
Plain-language definition
MOTS-c is the name of a very short protein fragment — a peptide of 16 amino acids — whose genetic instructions sit inside the mitochondria, the energy-producing compartments of the cell, rather than in the DNA of the cell nucleus. The name is an abbreviation of "mitochondrial open reading frame of the 12S rRNA type-c", which describes exactly where in the mitochondrial genome the sequence is read from. Researchers introduced the peptide in a 2015 report that described it as encoded within the mitochondrial 12S rRNA gene and examined its relationship to metabolic homeostasis, obesity and insulin resistance in cell and mouse models (PMID 25738459). In everyday terms, MOTS-c is studied as a signalling message that mitochondria appear to send to the rest of the cell. This page is for educational purposes only and is not medical advice; consult a licensed physician about any health question or decision.
What MOTS-c is in biochemical and regulatory terms
Origin and classification
MOTS-c belongs to a small family called mitochondrial-derived peptides (MDPs): peptides whose open reading frames are located in mitochondrial DNA. That classification matters because most peptides discussed in biology are encoded by nuclear genes. A 2023 review summarised MOTS-c as a mitochondrial-derived peptide of interest for therapeutic exploration and collected the mechanistic work published to that point (PMID 36761202).
Reported molecular actions
The original characterisation reported that MOTS-c acted on the folate–methionine cycle, which led to accumulation of the AMPK-activating intermediate AICAR and subsequent AMPK activation; in that work the peptide was reported to influence diet-induced obesity and insulin resistance in mice (PMID 25738459). A later study reported a second layer of activity: under metabolic stress such as glucose restriction and oxidative stress, MOTS-c translocated from the cytoplasm into the nucleus, where researchers reported it regulated nuclear gene expression, including stress- and antioxidant-response gene programmes (PMID 29983246). That finding is frequently cited as an example of mitochondrial retrograde signalling — information travelling from mitochondria back to the nucleus.
More recent work has looked for direct binding partners. A 2024 study reported that MOTS-c directly bound and activated casein kinase 2 (CK2) and that this interaction modulated skeletal muscle function in the models tested (PMID 39559755). Separate work in oncology models reported that MOTS-c suppressed ovarian cancer progression by attenuating USP7-mediated deubiquitination of LARS1 (PMID 39321430). Taken together, the literature describes MOTS-c less as a single-receptor ligand and more as a peptide reported to interact with several intracellular enzymes and transcriptional programmes depending on the model.
How the term is used in peptide research
In published research, "MOTS-c" is used in three distinguishable ways, and confusing them is a common source of error:
- As a gene product. The endogenous peptide encoded in mitochondrial 12S rRNA, measured in tissues, plasma or cell lysates.
- As an experimental agent. Synthetic MOTS-c administered to cells or animals to probe a pathway, as in the muscle, islet, liver and cartilage models summarised below.
- As a dependency marker. A pathway is described as "MOTS-c-dependent" when knockdown or loss of the peptide abolishes an observed effect. A 2024 study used this framing when researchers reported that pyrroloquinoline quinone alleviated mitochondrial damage in radiation-induced lung injury in a MOTS-c-dependent manner (PMID 39259217).
Where the term is misused
- Treating preclinical results as human outcomes. Most MOTS-c findings come from cultured cells and rodent models. A result reported in mice is not a demonstrated human effect.
- Calling it an "exercise mimetic" or "anti-ageing peptide" as if settled. The published abstracts describe specific mechanisms in specific models; sweeping performance or longevity labels overstate them.
- Confusing MOTS-c with humanin or the SHLPs. These are separate mitochondrial-derived peptides with distinct sequences and reported activities.
- Implying regulatory status. MOTS-c is not an approved drug product; synthetic material is generally labelled research-use-only, and "studied in a model" is not the same as "authorised for use".
- Quoting protocols the papers never contained. Many online summaries attach schedules and quantities to studies whose abstracts describe mechanism, not human dosing.
Doing the math on a vial? The PeptideU app does reconstitution, units and dilution for you.
Try it freeWhat the published literature reports
The table below summarises the direction of findings in the verified papers cited on this page. Each row reflects what researchers reported in that model; none establishes a human clinical outcome.
| Research area | Model context | What the study reported |
|---|---|---|
| Metabolism and insulin sensitivity | Cell and mouse models (PMID 25738459) | Action on the folate–methionine cycle with AICAR accumulation and AMPK activation; reduced diet-induced obesity and insulin resistance |
| Nuclear gene regulation | Metabolic stress in cells (PMID 29983246) | Translocation to the nucleus and regulation of stress-responsive nuclear gene expression |
| Skeletal muscle signalling | Muscle models (PMID 39559755) | Direct binding and activation of CK2 modulating muscle function |
| Muscle atrophy | Immobilisation model (PMID 38170165) | Attenuated immobilisation-induced atrophy by suppressing lipid infiltration |
| Myogenesis | In vitro muscle cells (PMID 35842023) | Promoted muscle differentiation in culture |
| Gestational diabetes | Preclinical GDM model (PMID 34798268) | Relieved hyperglycaemia and insulin resistance |
| Islet ageing | Pancreatic islet model (PMID 40855115) | Prevented islet cell senescence and delayed diabetes onset |
| Viral hepatitis | HBV infection models (PMID 37788894) | Antiviral role linked to mitochondrial remodelling |
| Joint tissue | Osteoarthritis model (PMID 41043625) | Attenuated mitochondrial dysfunction, pyroptosis and cartilage degradation via an Nrf2-dependent mechanism |
| Oncology | Ovarian cancer model (PMID 39321430) | Suppressed progression by attenuating USP7-mediated LARS1 deubiquitination |
Adverse Events: What Studies Report
The verified papers summarised on this page are mechanistic and preclinical, and the study abstracts focused on mechanism and model outcomes rather than on safety endpoints or tolerability in humans. The 2023 review noted the peptide's therapeutic interest while framing it as an area still under exploration (PMID 36761202). The founding characterisation likewise reported metabolic effects in cell and mouse systems and did not report human adverse-event data (PMID 25738459). Work in cancer models reported tumour-suppressive signalling rather than tolerability outcomes (PMID 39321430). Readers should therefore treat the absence of reported adverse events as an absence of data, not as evidence of safety.
Tracking research? Log entries with dates, lots and notes — records, never plans.
Get the appRelated terms a reader may encounter
- Mitochondrial-derived peptide (MDP) — the broader class MOTS-c belongs to (PMID 36761202).
- Humanin and SHLP1–6 — other mitochondrial-encoded peptides, distinct from MOTS-c.
- AMPK — the energy-sensing kinase activated downstream of AICAR accumulation in the original report (PMID 25738459).
- CK2 (casein kinase 2) — a kinase reported as a direct MOTS-c binding partner in muscle (PMID 39559755).
- Nrf2 / antioxidant response element — stress-response transcriptional machinery referenced in nuclear-signalling and cartilage studies (PMID 29983246, PMID 41043625).
- Retrograde signalling — communication from mitochondria to the nucleus, the framework used for the nuclear translocation finding.
Limitations of the current evidence
Three limits recur across the MOTS-c literature. First, the models are overwhelmingly cellular and rodent; the studies cited here describe mechanism in controlled systems. Second, effects are context-dependent — the same peptide is reported to act through AMPK, CK2, Nrf2 and ubiquitin-pathway proteins depending on the tissue examined, which complicates any single-mechanism summary. Third, endogenous MOTS-c concentrations, assay methods and administered forms differ between laboratories, so results are not always directly comparable. The 2023 review framed the field as promising but still in the exploratory phase (PMID 36761202).
Want the full course? Every compound, evidence-graded and cited, inside PeptideU.
Start learning freeReferences
- The mitochondrial-derived peptide MOTS-c promotes metabolic homeostasis and reduces obesity and insulin resistance (Cell Metabolism, 2015)
- The Mitochondrial-Encoded Peptide MOTS-c Translocates to the Nucleus to Regulate Nuclear Gene Expression in Response to Metabolic Stress (Cell Metabolism, 2018)
- The mitochondrial-derived peptide MOTS-c relieves hyperglycemia and insulin resistance in gestational diabetes mellitus (Pharmacological Research, 2022)
- MOTS-c promotes muscle differentiation in vitro (Peptides, 2022)
- MOTS-c: A promising mitochondrial-derived peptide for therapeutic exploitation (Frontiers in Endocrinology, 2023)
- Novel function of MOTS-c in mitochondrial remodelling contributes to its antiviral role during HBV infection (Gut, 2024)
- Mitochondrial-derived microprotein MOTS-c attenuates immobilization-induced skeletal muscle atrophy by suppressing lipid infiltration (American Journal of Physiology: Endocrinology and Metabolism, 2024)
- Pyrroloquinoline Quinone Alleviates Mitochondria Damage in Radiation-Induced Lung Injury in a MOTS-c-Dependent Manner (Journal of Agricultural and Food Chemistry, 2024)
- Mitochondrial-Derived Peptide MOTS-c Suppresses Ovarian Cancer Progression by Attenuating USP7-Mediated LARS1 Deubiquitination (Advanced Science, 2024)
- MOTS-c modulates skeletal muscle function by directly binding and activating CK2 (iScience, 2024)
- Mitochondrial-encoded peptide MOTS-c prevents pancreatic islet cell senescence to delay diabetes (Experimental & Molecular Medicine, 2025)
- MOTS-c attenuates mitochondrial dysfunction induces pyroptosis and cartilage degradation in osteoarthritis via an Nrf2-Dependent Mechanism (Free Radical Biology & Medicine, 2025)
Frequently asked questions
What does the name MOTS-c stand for?▾
MOTS-c abbreviates "mitochondrial open reading frame of the 12S rRNA type-c", which describes where its coding sequence sits in the mitochondrial genome. Researchers reported it as a 16-amino-acid peptide encoded within the mitochondrial 12S rRNA gene when they first characterised it in cell and mouse models (PMID 25738459). A later review grouped it with other mitochondrial-derived peptides (PMID 36761202).
How is MOTS-c different from ordinary peptides?▾
Most peptides studied in biology are encoded by nuclear DNA. MOTS-c is encoded inside mitochondrial DNA, which places it in the mitochondrial-derived peptide class described in a 2023 review (PMID 36761202). One study also reported that under metabolic stress the peptide moved into the nucleus and regulated nuclear gene expression, an example of mitochondria-to-nucleus signalling (PMID 29983246).
What mechanisms have researchers reported for MOTS-c?▾
The founding study reported action on the folate–methionine cycle leading to AICAR accumulation and AMPK activation in cell and mouse models (PMID 25738459). A 2024 study reported direct binding to and activation of casein kinase 2 in skeletal muscle (PMID 39559755), and a cartilage study reported effects on mitochondrial dysfunction through an Nrf2-dependent mechanism (PMID 41043625).
Has MOTS-c been studied outside metabolism?▾
Yes. Published work extends beyond metabolic models. Researchers reported an antiviral role linked to mitochondrial remodelling during hepatitis B virus infection (PMID 37788894), suppression of ovarian cancer progression through USP7-mediated LARS1 deubiquitination (PMID 39321430), and attenuation of immobilisation-induced skeletal muscle atrophy by suppressing lipid infiltration (PMID 38170165). These are preclinical models, not human clinical outcomes.
Is MOTS-c an approved medicine?▾
No. The verified literature summarised here consists of mechanistic and preclinical studies rather than approved-product data. A 2023 review described MOTS-c as a promising candidate still under therapeutic exploration (PMID 36761202), and the original characterisation reported findings in cell and rodent systems (PMID 25738459). Synthetic material is generally handled as research-use-only rather than as an authorised therapeutic.
What does "MOTS-c-dependent" mean in a study title?▾
It signals that an observed effect disappeared when MOTS-c was absent or reduced, implicating the peptide in that pathway. A 2024 study used this framing when researchers reported that pyrroloquinoline quinone alleviated mitochondrial damage in radiation-induced lung injury in a MOTS-c-dependent manner (PMID 39259217). It describes a mechanistic dependency, not a demonstrated clinical benefit.
What are the main limitations of MOTS-c research?▾
Findings come largely from cells and rodents, and mechanisms differ by tissue — AMPK in metabolism (PMID 25738459), CK2 in muscle (PMID 39559755), and Nrf2 in cartilage (PMID 41043625). Abstracts in this set focused on mechanism rather than human safety or tolerability, so absence of reported adverse events reflects absence of data rather than demonstrated safety (PMID 36761202).
Track it. Calculate it. Actually understand it.
References
This page summarises published research for education — it is not medical advice, and nothing here is a recommendation to use, purchase, or dose any substance. Study parameters described are what researchers reported, not instructions. Consult a qualified clinician before any health decision.